Thromb Haemost 1988; 59(03): 435-439
DOI: 10.1055/s-0038-1647511
Original Article
Schattauer GmbH Stuttgart

Aggregation of Human Platelets by Acidic Mucopolysaccharide Extracted from Stichopus japonicus Selenka

Jia-Zeng Li
*   Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China
,
Eric Chun-Yet Lian
The Veterans Administration Medical Center, Hemophilia and Thrombosis Center, Center for Blood Diseases, University of Miami, Miami, Florida, USA
› Author Affiliations
Further Information

Publication History

Received 06 May 1987

Accepted after revision 04 February 1988

Publication Date:
29 June 2018 (online)

Summary

The acidic mucopolysaccharide extracted from sea cucumber (Stichopus japonicus Selenka) (SJAMP) has been shown to cause platelets to aggregate. Using citrated platelet-rich plasma (PRP), washed platelets and formaldehyde-fixed platelets from humans, we investigated the effects of platelet inhibitors and various plasmas and their fractions on SJAMP-induced platelet aggregation. It was found that the lowest concentration of SJAMP required for the aggregation of human platelets was about 0.4 μg/ ml and the magnitude of aggregation induced by SJAMP was concentration dependent. The platelets were aggregated by SJAMP at 10 μg/ml in 25 out of 28 (89%) normal subjects tested. Platelet inhibitors such as PGE1, aspirin, indomethacin, apyrase, antimycin, 2-deoxy-D-glucose and EDTA inhibited by 70 to 100% the aggregation induced by SJAMP. Washed platelets alone were not aggregated by SJAMP. In the presence of fibrinogetr, washed platelets were aggregated by SJAMP, but formaldehyde-fixed platelets were not. These data indicate that the SJAMP-induced human platelet aggregation requires extracellular calcium, fibrinogen, and energy metabolism. The second phase of aggregation is dependent upon the release of ADP, and cyclooxygenase pathway.

 
  • References

  • 1 Fan HZ, Chen JD, Lin KZ. An acidic mucopolysaccharide isolated from Stichopus japonicus Selenka and some of its physical and chemical properties. Yao Hseuh Hseuh Pao 1980; 15: 264-270
  • 2 Li JZ, Bao CX, Chen GZ. Effect of acidic mucopolysaccharide extracted from Stichopus japonicus Selenka on hemostatic function. Chung Yao Tung Pao 1983; 8: 36-39
  • 3 Li JZ, Bao CX, Chen JZ, Zhang GZ. Antithrombin activity and platelet aggregation by acid mucopolysaccharide isolated from Stichopus japonicus Selenka. Acta Pharmacol Sinica 1985; 6: 107-110
  • 4 Wang H, Pan M, Huan X, Li S. Treatment of some thromboembolic disorders with SJAMP. Chin J Hematol 1985; 6: 596-698
  • 5 Walsh PN, Mills DC B, White JG. Metabolism and function of human platelets washed by albumin density gradient separation. Br J Haematol 1977; 36: 287-296
  • 6 Macfarlane DE, Kirby EP, Zucker MB. A method for assaying von Willebrand factor (Ristocetin cofactor). Thromb Diathes Haemorrh 1975; 34: 306-307
  • 7 Born GV R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
  • 8 Brace LD, Fareed J. An objective assessment of interaction of heparin and its fractions with human platelets. Semin Thromb Hemostas 1985; 11: 190-198
  • 9 Janson PA, Moake JL, Carpinito G. Aspirin prevents heparin-induced platelet aggregation. Br J Haematol 1983; 53: 166-168
  • 10 Saba HI, Saba SR, Morelli GA. Effect of heparin on platelet aggregation. Am J Hematol 1984; 17: 295-306
  • 11 Salzman EW, Rosenberg RD, Smith MH, Lindon JN. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
  • 12 Zucker MB. Heparin and platelet function. Fed Proc 1977; 36: 47-49
  • 13 Eika C. Inhibition of thrombin-induced aggregation of human platelets by heparin. Scand J Haematol 1971; 8: 216-222
  • 14 Eika C. The platelet aggregation effect of eight commercial heparins. Scand J Haematol 1972; 9: 480-482
  • 15 Cofrancesco E, Colombi M, Cristoforetti G, Pogliani EM. Selective PF4 release in vitro induced by heparin and related glycosaminoglycans (GAGs) - correlation with β-TG release and platelet aggregation. Thromb Haemostas 1984; 51: 105-107
  • 16 Blockmans D, Bounameaux H, Vermylen J, Verstraete M. Heparin- induced thrombocytopenia. Platelet aggregation studies in the presence of heparin fractions or semi-synthetic analogues of various molecular weights and anticoagulant activities Thromb Haemostas 1986; 55: 90-93
  • 17 McLean MR, Hause LL. The effect of bovine lung heparin on normal human platelets as measured by electronic particle size analysis. Thromb Haemostas 1982; 47: 5-7
  • 18 Chong BH, Grace CS, Rozenberg MC. Heparin-induced thrombocytopenia: Effect of heparin platelet antibody on platelets. Br J Haematol 1981; 49: 531-540
  • 19 Detwiler TC, Huang EM. Interactions of platelet activating pathways: Interrelationships of aggregation and secretion. In Platelet Responses and Metabolism. Holmsen H. (ed) CRC Press; Boca Raton, FL: 1986. 1 235-249
  • 20 Regoeczi EFibrinogen. In Structure and Function of Plasma Proteins. Allison AC. (ed) Plenum Press; New York: 1974. 1 133-167
  • 21 Ream VJ, Deykin D, Gurewich V, Wessler S. The aggregation of human platelets by bacterial endotoxin. J Lab Clin Med 1965; 66: 245-252
  • 22 Johnson H, Nicklasson PM. Effect of meningococcal and Escherichia coli capsular polysaccharides on human and dog platelet aggregation in vitro. J Clin Pathol 1976; 29: 438-440
  • 23 Nagayama M, Zucker MB, Beller FK. Effects of a variety of endotoxins on human and rabbit platelet function. Thromb Diathes Haemorrh 1971; 26: 467-473
  • 24 MacIntyre DE, Allen AP, Thone KJ I, Glauert AM, Gordon JL. Endotoxin-induced platelet aggregation and secretion. I. Morphological changes and pharmacological effects. J Cell Sci 1977; 28: 211-223
  • 25 Saba HJ, Saba SR, Morelli GT, Hartmann RC. Endotoxin-mediated inhibition of human platelet aggregation. Thromb Res 1984; 34: 19-33